TTM
−$3.19B
YoY change
-20.8%
5Y CAGR
—
Peak year (2021)
$12.20B
Cumulative net income
$6.01B
Net Income history chart for Moderna (MRNA) from 2016 to 2025
Latest: −$2.82B
Net Income growth chart for Moderna (MRNA) from 2016 to 2025
Latest: -20.8%
Net Income history table for Moderna (MRNA) from 2016 to 2025
| 2025 | −$2.82B | -20.8% | +$739.00M | ||
| 2024 | −$3.56B | -24.5% | +$1.15B | ||
| 2023 | −$4.71B | -156.4% | −$13.08B | ||
| 2022 | $8.36B | -31.5% | −$3.84B | ||
| 2021 | $12.20B | -1733.3% | +$12.95B | ||
| 2020 | −$747.06M | +45.3% | −$233.04M | ||
| 2019 | −$514.02M | +33.6% | −$129.29M | ||
| 2018 | −$384.73M | +50.3% | −$128.82M | ||
| 2017 | −$255.92M | +18.4% | −$39.70M | ||
| 2016 | −$216.21M | — | — |
- 2025−$2.82B-20.8%
- 2024−$3.56B-24.5%
- 2023−$4.71B-156.4%
- 2022$8.36B-31.5%
- 2021$12.20B-1733.3%
- 2020−$747.06M+45.3%
- 2019−$514.02M+33.6%
- 2018−$384.73M+50.3%
- 2017−$255.92M+18.4%
- 2016−$216.21M—
Net Income values are taken from Moderna's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Net Income at Moderna (MRNA)
According to Moderna's latest reported financial statements, the company's current net income (TTM) is −$3.19B. Net income is the bottom-line profit after all expenses — cost of goods sold, operating expenses, interest, and taxes — are subtracted from revenue. It is the figure used to compute earnings per share (EPS) and is the residual available to shareholders.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
2025's annual net income for Moderna (MRNA) came in at −$2.82B – declined 20.8% year-over-year.
Moderna net income peaked at $12.20B in 2021; the latest annual figure is −$2.82B in 2025 (123.1% below peak).
The record annual net income stands at $12.20B, reached in 2021; the historical low of −$4.71B was recorded in 2023.
Moderna Net Income by Year
Moderna Net Income 2025: −$2.82B
Moderna net income in 2025 was −$2.82B, declined 20.8% below 2024.
Moderna Net Income 2024: −$3.56B
2024's net income for Moderna came in at −$3.56B, declined 24.5% below 2023.
Moderna Net Income 2023: −$4.71B
Moderna posted net income of −$4.71B in 2023, plunged 156.4% below 2022. This figure represents the lowest annual value in the available history.
Moderna Net Income 2022: $8.36B
In 2022, Moderna reported net income of $8.36B, plunged 31.5% below 2021.
Moderna Net Income 2021: $12.20B
Moderna net income in 2021 was $12.20B.
See more financial history for Moderna (MRNA).
Sector peers by Net Income
Healthcare peers of Moderna (MRNA), ranked by their latest net income
| $26.80B | |
| $20.64B | |
| $18.25B | |
| $15.97B | |
| $12.06B | |
| $10.26B | |
| $7.71B | |
| $4.23B |
- $26.80B
- $20.64B
- $18.25B
- $15.97B
- $12.06B
- $10.26B
- $7.71B
- $4.23B
Frequently asked questions
Moderna (MRNA) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation